Your session is about to expire
← Back to Search
ELU001 for Ovarian and Endometrial Cancers
Study Summary
This trial is focused on subjects with advanced, recurrent or refractory FRα overexpressing tumors. ELU001 is a new chemical entity consisting of payloads and targeting moieties covalently bound by linkers to the C'Dot particle carrier. This is the first trial of its kind and a novel molecular entity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not taken treatments targeting the protein folate receptor alpha.You have a detectable viral load for HIV, hepatitis B, or hepatitis C.I have been diagnosed with a specific type of cancer such as ovarian, colorectal, or lung cancer.I can provide a sample of my tumor for testing before starting ELU001.I can take care of myself and am up and about more than half of my waking hours.My cancer can be measured by standard tests or, if not, it still follows certain criteria.I can care for myself and perform daily activities, but may be limited in work activities.I have no other treatment options that could significantly extend my life.I have no other treatment options that could significantly extend my life.My organs are working well.My cancer can be measured by standard tests or, if not, it still meets certain criteria.My organs are working well.My cancer can be measured by standard criteria or, if not, it still follows specific guidelines.I can care for myself and perform daily activities, but may be limited in strenuous physical work.I have no other treatment options that could significantly extend my life.I can provide a sample of my tumor for testing before starting ELU001.My organs are functioning well.I have fully recovered from my past surgeries.I have fully recovered from my past surgeries.I have no other treatment options that could significantly extend my life.I have an active eye condition.I can provide a sample of my tumor for testing before starting ELU001 treatment.I haven't had serious heart problems or other cancers in the last 3 years.You have very low levels of red blood cells, white blood cells, or platelets in your blood.I have been diagnosed with a specific type of cancer listed.My cancer has spread to my brain.I have fully recovered from my past surgeries.I have been diagnosed with a specific type of cancer such as ovarian, colorectal, or lung cancer.I do not have an active autoimmune disease needing immune-suppressing drugs.
- Group 1: ELU001
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different medical clinics is this medical study being run today?
"You can find this trial at 9 locations across America, with sites in New york, Durham, and Nashville. If you want to minimize travel, it would be best to select the centre closest to your home."
How many individuals are allowed to enroll in this clinical trial?
"That is correct. The information available on clinicaltrials.gov affirms that this study, which was originally advertised on September 13th 2021, is still recruiting patients. A total of 166 people are needed for the trial taking place at 9 hospitals or clinics."
Are we still enrolling people for this experiment?
"The information on clinicaltrials.gov indicates that this study is still recruiting patients. The trial was originally posted on September 13th, 2021 and was last updated on August 18th, 2022. The study is looking for 166 patients across 9 sites."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger